Countersurveillance

SpyAssociates.com Introduces Cutting-Edge MEFF M1-PRO Multifunction TSCM Kit, Unleashing New Capabilities in Technical Surveillance Countermeasures

Retrieved on: 
Monday, October 23, 2023
One Solution, Electronic, TSCM, Government, Organization, Law enforcement, Countersurveillance, Privacy, Private investigator, Cassette tape

BOCA RATON, Fla., Oct. 23, 2023 /PRNewswire-PRWeb/ -- SpyAssociates.com, a leading TSCM Equipment Solutions provider, is proud to announce the exclusive USA release of our revolutionary MEFF M1-PRO Multifunction TSCM Kit, designed to meet the evolving needs of the security industry in the USA. This groundbreaking technology is set to redefine the landscape of Technical Surveillance Countermeasures (TSCM) for businesses, government agencies, military, law enforcement, celebrities, and high net worth executives.

Key Points: 
  • This groundbreaking technology is set to redefine the landscape of Technical Surveillance Countermeasures (TSCM) for businesses, government agencies, military, law enforcement, celebrities, and high net worth executives.
  • Comprehensive TSCM Capabilities: Designed for TSCM professionals, corporate security clients, and government, military, and law enforcement agencies, the MEFF M1-PRO offers a comprehensive suite of technical surveillance countermeasures tools.
  • Comprehensive TSCM Capabilities: Designed for TSCM professionals, corporate security clients, and government, military, and law enforcement agencies, the MEFF M1-PRO offers a comprehensive suite of technical surveillance countermeasures tools.
  • We invite you to explore the future of TSCM with SpyAssociates.com's MEFF M1-PRO Multifunction TSCM Kit .

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Ohio State University, Antigen, Nanoparticle, AIM, MI, Solar cycle 1, CRS, American Society of Clinical Oncology, Clinical trial, DLT, Cancer, Bone marrow, Transplant, BMT, Chimera, Immunotherapy, Associate, Pleural effusion, Trial of the century, Șaeș, Acute myeloid leukemia, ASCO, City of Hope National Medical Center, AML, City, Influenza, MD, Patient, ECOG, Blood, Internal medicine, NEXI, PET/CT, Periodic breathing, Countersurveillance, Poster, Neoplasm, Phenotype, Society, Memory, Safety, Salvage therapy, Vaccine, Pharmaceutical industry, Medical imaging, Hematology

GAITHERSBURG, Md., June 05, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced results from its Phase 1/2 clinical trial of NEXI-001 in patients with relapsed/refractory acute myeloid leukemia (AML) post-allogeneic hemopoietic stem cell transplant (allo-HSCT). In this clinical trial to date, NEXI-001 is well tolerated with a favorable safety profile while eliciting an immune response to target antigens and a clinical effect in some patients. The data describing two patients from the dose escalation study of NEXI-001 are being presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago on Monday, June 5 at 8 AM in Hall A.

Key Points: 
  • “We have seen a clinical response maintained for seven months, which is an additional update from the data reported in our poster.
  • These data have established the ability of our AIM nanoparticles to expand healthy, multi-antigen-specific T cells with anti-tumor activity.
  • The data also show these T cells persist and maintain their memory phenotype at the site of tumor.
  • These data indicating both immunologic and clinical dose responses and observed durability in the patient at the higher dose support further clinical study of NEXI-001.

NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Retrieved on: 
Thursday, February 16, 2023
ACT, TAA, Countersurveillance, NEXI, Immunotherapy, Lymphocyte function-associated antigen 1, AIM, CD4, Maintenance, Immunological memory, Patient, Bi-specific T-cell engager, Neoplasm, Hackensack University Medical Center, Discovery, Associate, Biting, Innovation, Transplant, Observation, CD8, Hackensack Meridian Health, Vaccine

AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory.

Key Points: 
  • AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory.
  • The abstract describes the ability of multi-TAA AIM ACT T cells to work synergistically with BiTE therapy, revealing several important advantages over endogenous TAA nonspecific CD8 T cells + BiTE.
  • The results show that BiTE potency, as measured by a reduction in tumor burden in vivo, is markedly increased in the presence of AIM T cells.
  • This observation strongly suggests that AIM ACT T cells provide immunosurveillance following the withdrawal of the BiTE, a distinct advantage over bulk CD8+ T cells, which should contribute to the maintenance of remission.

Medikine Presents Preliminary Results of a Single-Dose Phase 1 Healthy Subject Study of MDK-703, a Peptide-Based Mimetic of Interleukin-7 (IL-7)

Retrieved on: 
Thursday, November 10, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Countersurveillance, IND, Degenerative disease, CD4, IL-7, Immunotherapy, Cytokine, ADAS, Technology, CD8, Drug discovery, Half-life, Infection, PD-1, Survival, Cancer, Human, Maintenance, Cell, NK, Patient, Therapy, Society, Blood, SITC, Pharmaceutical industry, Vaccine, Regulatory T cell

A second poster presentation detailed preclinical results in peripheral blood monocytes (PBMCs) from healthy donors for MDK-1654, Medikines dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINES.

Key Points: 
  • A second poster presentation detailed preclinical results in peripheral blood monocytes (PBMCs) from healthy donors for MDK-1654, Medikines dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINES.
  • This is the first demonstration of a synthetic peptide with agonist activity for two clinically relevant cytokine receptors.
  • In addition to activating both the IL-2/15Rc and IL-7Rc signaling pathways, MDK-1654 expanded all memory T cells, including CD8 Tscm.
  • Medikines lead candidate, MDK-703, currently in a Phase 1 clinical trial in healthy volunteers, is an IL-7 PEPTIKINE fused to an immunoglobulin Fc-domain.

Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients

Retrieved on: 
Monday, November 7, 2022
Private Securities Litigation Reform Act, Tumor microenvironment, Drug discovery, Ovarian cancer, FDA, Compugen, Population, Securities Exchange Act of 1934, Research, Annual report, U.S. Securities and Exchange Commission, ET, SEC, SITC, Company, Journal, B cell, Immunotherapy, Securities Act of 1933, Forward-looking statement, TLS, Security (finance), Society, Patient, Cancer, TIGIT, SVP, Nivolumab, DC, PVRL2, Neoplasm, Terminology, COVID-19, AstraZeneca, Society for Immunotherapy of Cancer, Risk, JITC, Q3, Compugen (Israeli company), Safety, TME, Poster, Nasdaq, Countersurveillance, TEL, Platinum, Bispecific monoclonal antibody, PD-1, NASDAQ, Drug Quality and Security Act, Vaccine, Pharmaceutical industry, Bayer, PVRIG

In addition to the data in the abstract, the Friday oral presentation will include new translational data from a number of platinum resistant ovarian cancer patients treated with COM701 monotherapy and from the fully enrolled MSS-CRC COM701 and nivolumab cohort.

Key Points: 
  • In addition to the data in the abstract, the Friday oral presentation will include new translational data from a number of platinum resistant ovarian cancer patients treated with COM701 monotherapy and from the fully enrolled MSS-CRC COM701 and nivolumab cohort.
  • "I believe the data we will present at SITC support the potential of PVRIG to open new possibilities in cancer immunotherapy," said Dr. Eran Ophir.
  • "The translational data are exciting because they support the anti-tumor activity we have shown with COM701 in combination with nivolumab in patients with MSS-CRC typically not responsive to approved checkpoint inhibitors.
  • Peripheral immune modulation was also seen with COM701 alone in a platinum resistant ovarian cancer patient with a partial response."

Medikine to Highlight Preclinical Data on its Lead Program MDK-703, an IL-7 Mimetic, at the 2022 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Wednesday, April 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Countersurveillance, IL-7, Therapy, Pharmacokinetics, Memory, Survival, Degenerative disease, CD4, Cancer, Poster, Infection, Drug discovery, CD8, Vaccine, Pharmaceutical industry

The poster highlights preclinical data on Medikines lead program MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikines innovative platform technology.

Key Points: 
  • The poster highlights preclinical data on Medikines lead program MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikines innovative platform technology.
  • PEPTIKINES are cytokine receptor agonists that are smaller in molecular size than, and structurally unrelated to, the natural cytokine proteins they emulate.
  • The poster presents data on the effects of MDK-703 on CD8, CD4, and memory T-cell populations in human cells in vitro and when administered to non-human primates and CD34-engrafted humanized mice.
  • Medikine is led by an accomplished team of industry veterans with decades of experience in pioneering drug discovery technology and developing immuno-oncology therapeutics.

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 13, 2021
FDA, DNA, PRIME, Safety, Company, Patient, IND, BCMA, Diagnosis, Therapy, Toxic shock syndrome, AAV, Neurotoxicity, Population, Clinical trial, ORR, Multiple myeloma, DLT, Division, ASH, Nasdaq, Investigational New Drug, Transposase, Multimedia, Survival, Society, U.S. Securities and Exchange Commission, Rituximab, Private Securities Litigation Reform Act, CRS, Twitter, Genetic engineering, University, ICU, SAN, Cytokine release syndrome, Countersurveillance, Security (finance), University of California, San Diego Performance-Based Skills Assessment, LinkedIn, Pharmaceutical industry, Vaccine, Medicine, Blood

The Company previously announced that it is winding down the P-BCMA-101 autologous program in favor of the allogeneic program, P-BCMA-ALLO1.

Key Points: 
  • The Company previously announced that it is winding down the P-BCMA-101 autologous program in favor of the allogeneic program, P-BCMA-ALLO1.
  • "Looking ahead, we continue to advance P-BCMA-ALLO1 and P-MUC1C-ALLO1 and look forward to presenting data in 2022 for both of these allogeneic programs."
  • The PRIME trial is a Phase 1/2, open label 3+3 single dose escalation of P-BCMA-101 CAR-T cells.
  • As of the data cut-off date of October 15, 2021, a total of 98 patients have been dosed with P-BCMA-101.

NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Mayo Clinic, Pakistan Society of Neuro-Oncology, Safety, Eli Lilly, Countersurveillance, Industry, PricewaterhouseCoopers, BMS, TMZ, Company, Novartis, Population, GBM, Cancer, Chemoradiotherapy, KOSDAQ, Amgen, Temozolomide, Progression-free survival, NIT, GSK, ALC, Society, Immunity, IL-7, SNO, HGG, Infection, Pharmaceutical industry, Vaccine

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.
  • The data show that NT-I7, a novel long-acting human IL-7, was well tolerated following chemoradiation in patients with high-grade gliomas (HGG), supporting continued evaluation in the Phase 2 portion of the study.
  • The median progression-free survival for MGMTp unmethylated GBM was 11.6 months, compared to 5.3 months commonly reported in chemoradiation studies.
  • Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data.

NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Chemoradiotherapy, NIT, SITC, Immunity, TMZ, Progression-free survival, Cancer, Industry, Novartis, Long-acting reversible contraception, Countersurveillance, Infection, Radiation, University, Merck, Clinical data management system, KOSDAQ, Temozolomide, Blood, Society, Pembrolizumab, NK, ALC, Eli Lilly, BMS, Tumor microenvironment, MD Anderson Cancer Center, IPR, IL-7, CPI, Society for Immunotherapy of Cancer, Neoplasm, Company, Merck Sharp & Dohme Federal Credit Union, Pancreatic cancer, Mayo Clinic, ORR, Immunotherapy, CD8, H. Lee Moffitt Cancer Center & Research Institute, PricewaterhouseCoopers, Poster, PFS, Patient, GSK, HGG, Merck & Co., RECIST, Amgen, Pharmaceutical industry, Medical imaging, Vaccine

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented new data from two clinical trials evaluating the companys lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in three posters at the Society for Immunotherapy of Cancer (SITC) annual meeting.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented new data from two clinical trials evaluating the companys lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in three posters at the Society for Immunotherapy of Cancer (SITC) annual meeting.
  • The interim analysis of the phase 2 met the primary endpoint of overall response rate (ORR) in these cohorts.
  • The median follow-up of the efficacy data was ~5.8 months in the MSS-CRC Cohort and ~4.6 months in the Pancreatic Cancer Cohort.
  • Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data.

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

Retrieved on: 
Tuesday, August 31, 2021
Molecule, Company, Cytokine release syndrome, Webcast, Private Securities Litigation Reform Act, Therapy, Associate, Twitter, MCRPC, U.S. Securities and Exchange Commission, Dose, AAV, Neurotoxicity, Diagnosis, ID, Security (finance), Memorial Sloan Kettering Cancer Center, Nasdaq, AML, MAS, Mechanism, Transposase, Immunotherapy, Multimedia, Investor, Multiple myeloma, CRS, Countersurveillance, Safety, Adult, Patient, SAN, Durable, LinkedIn, Metastasis, Acute myeloid leukemia, Prostate, Genetic engineering, Prostate cancer, Bone marrow, Neoplasm, Macrophage activation syndrome, Technology, Chromosomal translocation, Vaccine, Pharmaceutical industry

Patients were heavily pre-treated, having received an average of six prior lines of therapy with a median time since diagnosis of 6.4 years.

Key Points: 
  • Patients were heavily pre-treated, having received an average of six prior lines of therapy with a median time since diagnosis of 6.4 years.
  • "This is the first time that I have seen such impressive responses with an immunotherapy product.
  • The Phase 1 trial is an open label, multi-center, 3+3 dose-escalating study designed to assess the safety of P-PSMA-101 in up to 40 adult subjects with mCRPC.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.